<DOC>
	<DOCNO>NCT02224118</DOCNO>
	<brief_summary>The purpose study investigate safety ( adverse event , weight , blood pressure , pulse rate , body temperature , abdominal ultrasonography , standard 12-lead electrocardiography , laboratory test ) CNTO 3649 administer subcutaneous injection healthy adult Japanese men week 4 week Japanese participant type 2 diabetes mellitus ( disorder decrease insulin body body 's insulin effective , result high blood sugar , increase thirst urine , many side effect ) .</brief_summary>
	<brief_title>Safety , Pharmacokinetics , Pharmacodynamics Study Single Dose CNTO 3649 Healthy Adult Men Multiple Doses CNTO 3649 Participants With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This Phase 1 , multi-arm open-label ( know intervention study ) study explore safety , pharmacodynamics ( study drug act body ) pharmacokinetics ( study way drug enters leave blood tissue time ) CNTO 3649 . The study divide Part 1 2 . Part 1 include healthy adult Japanese men Part 2 include Japanese participant type 2 diabetes mellitus . The healthy adult Japanese men part 1 receive single dose either 10 , 30 , 100 300 microgram/milliliter ( mcg/mL ) CNTO 3649 participant part 2 receive subcutaneous dose either 30 100 mcg/mL CNTO 3649 week 4 week . The study Screening period 28 day Part 1 42 day Part 2 . Participants primarily assess safety ( adverse event , weight , blood pressure , pulse rate , body temperature , abdominal ultrasonography , standard 12-lead electrocardiography , laboratory test ) . The total duration study 57 day Part 1 92 day Part 2 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Part 1 Weighs great equal ( &gt; = ) 50 kilogram ( kg ) less ( &lt; ) 100 kg body mass index ( BMI ) &gt; = 18.5 &lt; 25.0 time screen test Is nonsmoker , able refrain smoke 2 day screen test completion posttreatment examination followup investigation Is able refrain consume alcohol 2 day screen test completion screen test , 2 day hospitalization ( Day 4 ) discharge ( Day 8 ) , 2 day clinic visit ( Days 13 20 ) completion test clinic visit ( Days 15 22 ) , 2 day posttreatment examination followup investigation completion posttreatment examination followup investigation Has agree use medically acceptable form contraception ( example [ eg ] , condom ) day hospitalization ( Day 2 ) completion posttreatment examination followup investigation Has clinically problematic abnormality medical examination test study treatment Part 2 Weighs &gt; = 50 kg &lt; 100 kg BMI &gt; =18.5 &lt; 37.0 time screen test Was diagnose type 2 diabetes mellitus least 3 month screen test stably manage dietary modification , exercise therapy , sulfonylureas biguanides If sulfonylureas biguanides use , use fix dosage stably manage disease since least 3 month screen test If participant hyperlipidemia , stably manage antihyperlipidemic drug fix dosage since least 3 month screen test If participant hypertension , stably manage antihypertensive drug fix dosage since least 3 month screen test Is nonsmoker , able refrain smoke hospitalization period 1 day clinic visit day completion test Part 1 Has hepatic , renal , central nervous system ( include psychiatric ) , cardiovascular , respiratory , gastrointestinal , hematopoietic , ophthalmic , infectious , endocrine disease would make participant unsuitable study participant Has malignant tumor within 5 year study treatment Has undergone surgery would make participant unsuitable study participant within 12 week screen test Has acute disease occur within 7 day study treatment Has eating disorder ( pathological anorexia bulimia ) Part 2 If dietary modification exercise therapy use , fast blood glucose &lt; 130 milligram per deciliter ( mg/dL ) &gt; = 270 mg/dL screening test hospitalization ( Day −1 ) . If oral antihyperglycemic drug use , fast blood glucose &lt; 100 mg/dL &gt; = 240 mg/dL time screen test &lt; 120 mg/dL &gt; = 270 mg/dL hospitalization ( Day −1 ) If dietary modification exercise therapy use , HbA 1C time Screening test &lt; 6 % &gt; = 10 percent ( % ) . If oral antihyperglycemic drug use , HbA 1C time screen test &lt; 6 % &gt; =9 % Has blood pressure pulse rate outside follow range , hypertension blood pressure pulse rate outside follow range despite take antihypertensive drug dosage since least 3 month screen test Has type 1 diabetes mellitus Has autoimmune diabetes mellitus</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>CNTO 3649</keyword>
</DOC>